MARK YOUR CALENDARS! Want to be the first to know when registration opens? Sign up here: https://lnkd.in/eXuAY3DR
Cycle for Survival
Non-profit Organizations
Cycle for Survival is the movement to beat rare cancers. Every dollar raised goes to research at MSK.
Über uns
Cycle for Survival is the movement to beat rare cancers. 100% of every dollar raised is directly allocated to rare cancer research at Memorial Sloan Kettering Cancer Center (MSK) within six months of the close of fundraising annually. Cycle for Survival has raised over $376 million since it first began in 2007. This milestone reflects the determination and generosity of our passionate community. Approximately 50% of people with cancer are battling a rare cancer, but they often have limited or no treatment options because rare cancer research is drastically underfunded. Together with founding partner, Equinox, Cycle for Survival funding has supported pioneering clinical trials, research studies and major scientific initiatives at MSK, leading to new and better treatment options for patients worldwide. To learn more about corporate impact, go to cycleforsurvival.org/corporate To sign up to ride: cycleforsurvival.org/ride-with-us To donate: cycleforsurvival.org/donate Follow us on Facebook (Cycle for Survival), Twitter (@Cycle4Survival), Instagram (cycleforsurvival), and TikTok (cycleforsurvival).
- Website
-
https://www.cycleforsurvival.org
External link for Cycle for Survival
- Industrie
- Non-profit Organizations
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Typ
- Nonprofit
Employees at Cycle for Survival
Aktualisierungen
-
From high-energy rides to heartwarming moments, a Cycle for Survival event is a celebration of strength and community. Register now for a 2025 event: https://lnkd.in/eeZaSx6c
-
All of us can make a difference. Register now for a 2025 #CycleforSurvival event and ride to support rare cancer research at Memorial Sloan Kettering Cancer Center. Sign up here: https://lnkd.in/eeZaSx6c
-
We’re kicking off the 2025 season with a big fundraising boost! 🚀 Once you start a team, fill it with at least four riders per registered bike by September 16 to receive a $300 donation to your team’s fundraising page! #CycleforSurvival
-
All of us can make a difference. Register now for a 2025 #CycleforSurvival event and ride to support rare cancer research at Memorial Sloan Kettering Cancer Center. Sign up here: https://lnkd.in/eeZaSx6c
-
REGISTRATION OPENS TOMORROW! Cycle for Survival is a community united by a lifesaving cause: funding rare cancer research at Memorial Sloan Kettering Cancer Center that brings hope and new cures to people everywhere. This mission keeps us going year-round, but when we come together, our energy, passion, and courage reach new levels. We’re hosting indoor rides in 15 cities next January, February, and March with our founding partner, Equinox. Registration starts tomorrow, and we can’t wait for you to join us! #CycleforSurvival
-
Luke Weber, a pediatric cancer survivor and long-time Cycle for Survival champion, used his experience as a Memorial Sloan Kettering Cancer Center patient to help create the "iSleep Team," an initiative created to improve sleep for patients without compromising their care. Read more about this incredible program here.
-
New cities, same mission. We’re heading to over 15 locations between January and March, including new rides in: Darien, CT Paramus, NJ New York City Sign up here to be the first to know when registration opens: https://lnkd.in/eXuAY3DR
-
New York! Are you ready for 2025 rides? We're back February 5–8 and March 5–9. Be the first to know when registration opens: https://lnkd.in/eXuAY3DR
-
Neuro-oncologist Ingo Mellinghoff, MD, whose work has been funded by Cycle for Survival, led the clinical trial on a new drug to treat low-grade brain tumors. This is the first treatment of its kind in over 20 years.
The US Food and Drug Administration (FDA) has approved a new drug that slows the growth of low-grade diffuse gliomas with a certain gene mutation. "This represents the first new treatment option in low-grade diffuse glioma in more than 20 years.,” says Dr. Ingo Mellinghoff, Chair of Department of Neurology at Memorial Sloan Kettering Cancer Center (MSK), who led a clinical trial showing the drug’s effectiveness. The drug, vorasidenib, targets a mutation in IDH genes, which are present in 80% of low-grade gliomas. IDH-mutant gliomas make up about 20% of diffuse gliomas in adults, by far the most common malignant primary brain tumors. Learn more: https://bit.ly/3LWniUV